It is important to note that anti‐PDL1 monoclonal antibodies have been shown to be ineffective or only marginally effective in CRC during clinical trials, and thus their standalone use has not been incorporated into clinical guidelines.[25] The results indicated that, although the combination of RT and anti‐PDL1 could temporarily control tumor growth, tumors typically recurred within 1–2 weeks following the cessation of treatment. Here, CD274 is linked to neoplasm.